ORCHID PHARMA LIMITED

Highlights Orchid Pharma Limited Bombay S.E.

Equities

ORCHPHARMA

INE191A01027

Market Closed - Bombay S.E. Other stock markets 06:00:48 2024-04-30 am EDT			5-day change	1st Jan Change
1,077 ^INR	-0.84%		+2.37%	+50.95%

Apr. 12	Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director	CI
Feb. 23	Orchid Pharma Receives United States Food and Drug Administration Approval for Its Novel Invention	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Orchid Pharma Receives United States Food and Drug Administration Approval for Its Novel Invention	Feb. 23	CI
Orchid Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
European Medicines Agency Grants Approval for Orchid Pharma's 'Exblifep'	Jan. 30	CI
Orchid Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 04	CI
Orchid Pharma Ties Up with GARDP to Manufacture Antibiotic for Certain Gram-Negative Infections	23-09-12	MT
Orchid Pharma Limited Enters into Manufacturing Sub License Agreement with Global Antibiotic Research & Development Partnership	23-09-12	CI
Orchid Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Orchid Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-10	CI
Orchid Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-09	CI
Orchid Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Reverse Split: 1 of 219.298203	19-07-24	FA
Ex-dividend day for final dividend	12-09-12	FA

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer